The ShiftShapers Podcast
Change either paralyzes or energizes - the choice is yours. Hear from businesses and entrepreneurs who have become energized and who have profited by shaping the shifts in their markets and practices. Become a SHIFTSHAPERS INSIDER and get our latest download, advance notice of all podcasts, podcast summaries, and special INSIDER-ONLY content. INSIDER SIGN UP
The ShiftShapers Podcast
Ep #310: The Genomic Revolution - With Darren Rowe
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
This episode of The ShiftShapers Podcast is called "The Genomic Revolution - with Darren Rowe". Today, host and Chief Transformation Strategist David Saltzman and Darren explore the current science of genomics and the potential it holds for precision medicine in the future.
Darren also raises the important social and ethical elements that are inherent with genomics, such as the role of wealth and the possibility of breeding superhumans based solely on their capacity to access this technology. Darren also explains how ROI can be determined in the early stages of genomics today.
What You’ll Learn From this Episode:
- 04:20 The Genomic Revolution defined
- 07:55 Applying genomics
- 11:25 Genetic editing: a social and ethical question
- 14:29 Precision medicine & insurance companies
- 19:30 Demonstrating the ROI of genomics
Quotes:
03:26 “What are some things that you might want to think about when you’re purchasing a group plan for your employees? Maybe come up with a top 10 things that people need to recognize.”
08:13 “Anytime you can share a story, you’re touching people. They’re getting to know you better. You’re able to reach out and really say hey, I can identify with you. I get it. I’ve experienced this too. So stories are vital.”
17:47 “You’ll always get business from the audience if you present good content and you do some of the tips I shared earlier. But be negotiable.”
18:02 “Speaking should be used as a paid marketing tool for you to get more clients, for you to get in front of those audiences, to get those private speaking training or speaking gigs as well.”
21:11 “The best way to deal with fear is feel the fear, do it anyway, because you’re up there. You just have to get started.”
There's a genomic revolution underway. It will affect your clients. It'll affect healthcare spend, and it will affect user experience. How will this revolution change things and what do you need to know? We'll find out on this episode of Shift Shapers.
AnnouncerChange either paralyzes or energizes. The choice is yours. You're listening to the Shift Shapers podcast. You're about to learn firsthand from businesses and entrepreneurs who have successfully shaped the shifts in their industries. Get ready to become the change you want to see. This episode is brought to you by Shift Shaper Strategies. In sales, if you confuse, you lose. Clarify your message so you win more clients, crush your sales goals, and build your practice. Learn more at ShiftShaperStrategies.com. And now, here's your host, Story Brand Certified Guide and Chief Transformation Strategist at Shift Shaper Strategies, David Saltzman.
DavidOn this episode of Shift Shapers, we're talking with Darren Rowe. Darren is the Chief Innovation Officer at Womburg Genomic Advisors. Now, we've spoken a little bit about genomic testing back in episode 224 with our friend Joe Spinelli. And that was kind of a more narrow topic, I think. What Darren is working on and his expertise is a bit broader, but I'll let him explain that with that. Welcome, Darren. Good morning. Thank you. So talk a little bit about, because I think it informs the rest of our conversation. Talk a little bit about your journey and your background, please.
SPEAKER_02Sure, yeah. So I spent a good part of my career in pharmaceuticals, so working for big pharma companies in various roles. I then slowly started to work towards smaller companies, and I ended up working with a number of pharmaceutical startup companies, which is very interesting, but still within the context of oncology and genomics. And then around about 2006, I got a chance to work with Johns Hopkins, who had spent quite a lot of time trying to figure out how individuals react and respond to chemotherapy. And they'd come up with a very novel way of doing that. And they'd been able to raise enough money to launch a business called Champions Oncology, and they asked me if I would launch that for them into the European market. So that was very successful. It was very innovative at the time, and the technology was incredibly expensive, hundreds of thousands of dollars. So we really focused on very high net worth individuals who had cancer at that time, and we were really just trying to prove the concept. To make a long story short, that business continued to do well, and that went public. And then I left that company and I set my own company up. And that was really based on the fact that cancer, as we all, I'm sure can appreciate, is an incredibly challenging disease on many levels. And having spent you know the last sort of five years before that working with cancer patients, albeit they they were generally pretty wealthy people, they still had the same issues that everybody else has. And it was really around you know, how do you navigate through this process, how do you make decisions, how do you access good quality technology, you know, how do you know what to believe, who to believe, and so on. So the company I set up was really designed to address some of those challenges, and that again that did pretty well. And then from there, I had you know, I was married to an American wife, and so we decided about two years ago that we would leave that business. So we sold that and we moved over to the US, and that's when I met the founders of WGA, and I guess the rest is history. So I've I've spent a lot of my time understanding cancer, understanding healthcare, and understanding the role that genomics and genetics has in that field, but also understanding what some of the sort of operational challenges are in making these sort of technologies available. And that's really my area of expertise, of that sort of last mile, if you like, you know, how to, I guess, democratize access to some of this really cool technology.
DavidWell, and that's that's a great run into our next question, which is you folks talk about this thing called a genomic revolution. What is that? How do you see that?
SPEAKER_02I think it's really based on the you know the simple premise that our genome is essentially the blueprint of who we are, and it holds the key to so many questions that have thus far remained unanswered. So, you know, the application of genetics can help us understand risk, risk of disease. It can help us understand how we might respond to certain medications, it can inform us that certain medications may not work for us and in some cases could even be detrimental to our health. Should we become ill, genomics also has the power to help us understand what type of medication would specifically work for us on a one-to-one level. So there's a lot of excitement around genomics, and then if we take that further, you know, we're now talking about proteomics, we're talking about gene editing. So you may have heard of CRISPR. We're at that point now where we can edit a genome and effectively resolve problems at a genetic level, which is phenomenal. So we've I think reached that point now where the science is sufficiently good that it now has real-world applications. It's not theoretical, you know, it's robust, it's consistent. For the most part, it's relatively affordable, not across the board. There's elements of what I've just mentioned that are still, you know, I would guess experimental and very expensive. But you know, there are big areas now of our lives that we we can start to incorporate genomics into a relatively affordable price. And I think when we talk about the genomics revolution, we're really talking about how genomics is going to impact our lives and you know how we can build services and programs that allow us access and allow us to benefit from some of this amazing technology.
DavidIn the average population, would in today's world would you target mostly around cancer, or are there other diseases that are in that more affordable, more quote unquote pedestrian kind of a range?
SPEAKER_02So cancer for us is a kind of an obvious place to begin this journey because it's a complicated disease, it's a disease of the gene. So cancer occurs when essentially one of your genes malfunctions and you know creates cellular problems down the line. It's expensive, it's you know incredibly scary, it affects about one in two or one in three of us. So it's something that for most people, sadly, they will experience in one way or another. If it's not them, it'll be someone in their family. So it's a good place to start. And I think if we can apply genomics in a sensible way that that shows a you know a demonstrable benefit in terms of outcome. And I'm talking about outcome not just in terms of you know recovery, but I'm also talking about your experience of genomics. You know, I ideally, you know, if you're diagnosed with cancer, you you want to find a treatment that works quickly. That treatment ideally should be you know relatively inexpensive, or it should there should be some mechanism around it that allows you to access it, so you shouldn't go bankrupt. The side effects of that treatment should be tolerable. You you know, you ideally you'd be able to continue work, you'd get all the support you need, you know, you you would be managed and placed into an environment that gives you the best opportunity for an outcome. And and cancer is that perfect disease because it is so multifaceted and it's it's so complicated. So I think that's where we start. But to answer your question, there's a lot of very exciting applications of genomics, and we're seeing genomics being applied to all kinds of diseases, all kinds of therapy areas. I had a very interesting conversation two weeks ago with a company based in on the East Coast, just outside Baltimore, and they've established a gene, a genetic connection with post-traumatic stress syndrome, which is really interesting because now they, you know, they're working towards being able to predict who is likely to suffer from PGSD. Now that just opens up a whole world of new possibilities and it allows first responders, members of the military to better prepare, to put plans in place before they're deployed. I think every area of our lives will be impacted eventually by genomics.
DavidLong term, do you feel that the predictive implications are actually the gold standard? They're the thing that really is the most important? As opposed to, you know, determining treatments and after the fact, after a disease is diagnosed?
SPEAKER_02Yes. I mean, ideally, we want to be able to get to the point where we can predict a disease before it happens. Ideally, we want to take that further, and this is where we start getting into some of the ethical questions. But you know, in an ideal world, we'd like to be able to identify risk in an individual and then have the ability to modify that risk at a genetic level. And that's where we get into gene editing. And I guess that's that's the ultimate situation to be in. I don't know whether we'll get to that point in my lifetime. Scientifically, we have made big steps, and there are certain things that we can do now. As I mentioned, CRISPR enables us to essentially edit the genome and you know, replace or remove some of those damaged genes that create that cause disease. Then it kind of opens the door to other conversations that frankly have to happen at a sort of you know an ethical, regulatory, uh, moral level, I think before we can really go any further. So again, to answer your question, I think predicting disease is fantastic, and that's kind of where we're at now. Ultimately, we're going to get to the point where we can not just predict disease, but we can we can change the course of you know your own health on an individual basis. That's really where we're heading.
AnnouncerAnd now, a word from our sponsor. It's a fact. Salespeople and organizations lose opportunities because they don't clearly communicate their value. In today's market, your story is your message. It should be crystal clear, perfectly arranged, and precisely targeted to attract the clients you want. As a certified story brand guide, we use the exclusive SB7 process to create that story and the websites and collateral that deliver it. If your message isn't cutting through the noise, we can help. Visit us at ShiftShaperstrategies.com to learn how we can help you find, clarify, and deliver a message that wins clients, crushes sales goals, and builds your practice. In sales, if you confuse, you lose. So learn more and schedule that call today at Shiftshaperstrategies.com. That's Shiftshaperstrategies.com. And now back to our discussion.
DavidFrom an individual perspective, though, you talked about CRISPR and I know there's some other burgeoning techniques. Do you think that widely accepted genetic editing is really the key to broader acceptance of genetic testing?
SPEAKER_02And in what respect? What do you mean?
DavidWell, in other words, if I'm an individual and I know I can get genetically tested and I can find out about conditions that I may have or predilections that I might have for disease, but there's nothing that can be done about it. My question is, do I really want to know about it? Yeah. But if on the other hand, there are widely accepted techniques where if I have this particular gene or a mutation of a gene and I can they can go in and fix it, then sure I want to know about it.
SPEAKER_02Yeah. That's a big question that I think a lot of people are still wrestling with. And you know, there's some research looking at the sort of social aspect of this and how people are likely to respond to some of these scientific processes. You know, we know that there are some people who, if you take Alzheimer's as an example right now, you know, we we can do a genetic test to determine whether you're at risk or a higher risk of developing Alzheimer's. Um, but there's not too much that we can do about that. Now there are some people that want to know, you know, even though there's not much that you can really do about it, there are a lot of people that want to know. They want to use that knowledge to, I guess, help them manage their estate, make sure that they've got everything in order. They're probably amongst that group, I'm sure there's a a lot of very determined individuals who don't believe that there's nothing they can do. You know, there's anecdotal evidence, I think, that reading and various other things, you know, puzzles of the mind and so on. I think there are probably some things that you can do. And I'm sure there's a a whole group of individuals who who believe that and will take positive action. But as you said, there's also a you know, a large group of the population who don't want to know because what's the point? You know, you're you're you're really just telling me something which potentially makes me quite miserable and I can't do anything about. So that's still very much an issue for for the types of diseases, you know, like Alzheimer's and so on, that where we don't really have much of a solution beyond being able to predict it. I don't know what the number is, whether it's 50-50, I don't know, but there's certainly a you know a group of people that want to know and a group of people that don't want to know. But I think as we gain a better understanding of these diseases and as we develop you know better medication and you know, even medications that can be taken prophylactically, I suspect that balance will over time start to tip. But then we start getting into the equality question, you know. There will always be the haves and the have nots. So, you know, if we're not careful, we could breed a species of human that is essentially superhuman based on the fact that they had the resources to access some of this technology, and then we'll have a a subgroup of people who don't have access to that type of technology, and they'll continue to get diseases and they'll continue to die, and we'll almost have a master race. That's probably been a little bit dramatic. But you know, these are the questions and these are the real issues that I think we, you know, we have to start wrestling with.
DavidFrom a more practical standpoint, is this kind of testing currently mostly applicable to partially self-funded medical plans, or are you having conversations with some of the large fully insured carriers as well about incorporating it?
SPEAKER_02For the most part, it's self-funded. I mean, that was part of the problem WJ tried to solve. There is, I think, an inherent problem with precision medicine. You know, the sort of global term for what we're discussing is precision medicine based on, I know, uh a form of medication being delivered to an individual in a very precise way that's relevant just for that individual. And that's the basis of genomics. And this this new field of precision medicine or personalized medicine, it opens up a whole sort of plethora of new new challenges and new questions, and particularly when you start looking at reimbursement and insurance companies, because frankly, they're not structured to deal with this. I call it the you know, N of one. So, you know, N of one is essentially a clinical trial that consists not of a whole population or tens of thousands of people, like we are used to seeing an N of one clinical trial involves just one individual. And if the drug or the solution that you're testing in this N of one population works for one individual, then it's a success because it's a personalized solution. Now that is a very difficult concept for insurance companies to manage because everybody is different. So, how do you control what type of a drug is prescribed for disease A, if in theory it could be anything, because one individual will respond to one drug, another individual will respond to another drug, another individual may respond to a drug that you haven't even thought about. So now you put a lot of trust in doctors, you put a lot of trust in technology, and it becomes very difficult to manage financially. We've also, I think, at the moment got a situation where there's just not enough understanding about the quality of these tests. So there are 70,000 different genetic tests on the market right now, but there are only 200 CPT codes. So, what does that tell you? It tells you that we're a long way from being able to categorize these tests, understand their true value. There's very little research being done on validating or assessing one test against another. Most of the research and most of the investment that goes into genomics is really focusing on finding new genetic markers and you know developing new tests. There's not been a lot of work done comparing one test versus another. So that makes it difficult for insurance companies. That also means that it's difficult to sort of develop protocols around medical necessity. 70,000 tests, a community of doctors that aren't all equally informed when it comes to genomics. Remember, a lot of doctors that are at that senior level now went through medical school before this was even a thing. I mean, we weren't really teaching this in medical school. And even now, there's, as I understand it, there's not an awful lot of emphasis on genomics. It's almost like a tick box exercise that you do on your way out as you finish. You know, we've got some knowledge gaps amongst the the medical community, we've got some sort of financial validation issues, I think. You know, we've got some issues around understanding medical necessity. And then from insurance companies' perspective, I think the final issue is that they just don't have the number of genetic experts that they need. There's just not enough. So if you look at a typical insurance company, you know, your chief medical officer is unlikely to be a geneticist at this point. They're more likely to be a general practitioner, an internist. Occasionally you'll get an expert in a particular medical field, but for the most part, you know, because they're dealing with a very broad set of issues, they tend to be generalists. And now we're asking them to make decisions about genetics, which is a highly complex and incredibly specialized field of medicine. And I just don't think they're they're ready for it. So I think this is a natural sort of evolution. To me, it feels like the science is moving quicker than the rest of the world, and I think the rest of the world has to catch up on all of those levels I've mentioned. And so for the most part, we are dealing with companies that either self-insure or they recognize that our solution could potentially solve some of those issues. So that's that's essentially where we're at now.
DavidWe've got just a minute or two left. And I guess the for so for a partially self-funded plan, I don't think there's any question that you can have a significant discussion today about better patient experience. But it all comes down to money in the plan. A plan has to act in the fiduciary best interest of all the members of the plan. So how do you demonstrate ROI at this early stage?
SPEAKER_02That's a very good question, a question that everybody asks. And honestly, it would take me one hour to answer that comprehensively. So let me give you, let me give you the sort of a bridge version. There are elements of our program that have been developed using systems and resources and services that are well established. So we have a pathology review as an example. You know, we have nurses that can be deployed on site and so on. So the genomics is just one component of a much broader solution because genomics, for all it's worth, is still only one small part of the healthcare journey. There's a lot of other components to it. And so we built a solution that has at its core a genomics foundation, but it also has all these other components. So the other components are very well established and they do have an ROI. You know, there's an example if you can reduce the likelihood of a misdiagnosis through a pathology review, then there's there's an ROI there. So that addresses some of those issues. The second part to that question is that it really depends on what you as an organization defines as an ROI. Because I could play devil's advocate, if you're talking about an ROI purely from a fiscal perspective, there's there's a lot of ways you could do that. The question is: does what you're doing now for your employees as it relates to healthcare and benefits support the culture that you're trying to nurture? So I think there's a much broader question there that goes beyond sort of the Excel spreadsheet dollar balance. I think you have to be sensible, and I think it's irresponsible to put things in place that cost huge amounts of money and give you no return. But I think you have to broaden your understanding of what an ROI is, and that I think is where we're at now. Now that said, there are clearly some very good data around genomics in certain groups, cancer profiling in certain patient groups, that would suggest you know the outcome is better and the cost is less, and you know, people get onto the right drugs quicker and so on and so on and so on. But that's not, I don't think, at the point yet where we could say 100%, you know, deploy this program and you will save money. I think it's a much broader conversation because it has a lot of moving parts. That may or may not have answered your question, but I I hope it did.
DavidNo, I I think I think it did as good a job as we're going to do for today, because unfortunately, we're out of time and we don't have an hour. Although we'd love to have you back at another time. There's going to be more and more to talk about in this field as you folks go along. Darren Rowe, Chief Innovation Officer at Womburg Genomic Advisors. Darren, thank you so much for sharing your expertise with our audience. You're very welcome. Thank you.
AnnouncerThe Shift Shapers Podcast is a production of Shift Shaper strategies and may not be reproduced or quoted in whole or in part without our express written permission. Copyright 2020. All rights reserved.